Press Release February 16, 2021

Adicet Bio, Inc. Announces Closing of $152 Million Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

The Life Sciences team advised Adicet Bio, Inc. (Nasdaq: ACET) on its underwritten public offering of 10,575,513 shares of its common stock, including the exercise in full by the underwriters of their option to purchase up to an additional 1,344,743 shares of common stock at a public offering price of $13.00 per share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses were approximately $137.5 million. In connection with the offering, Adicet entered into a stock purchase agreement with certain existing investors for $15.0 million of shares of its common stock at a price per share equal to the public offering price, with an initial closing for certain investors held simultaneously with the closing of the offering and a subsequent closing for certain additional investors.

 

Adicet is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases.

 

The Goodwin team was led by Danielle Lauzon, Mitchell Bloom, Gabriela Morales-Rivera, Jason GoldfarbKathryn WestonStephanie Philbin, Roger Cohen, Elizabeth Mulkey, and Andrew Hess.

 

For more details, read the press release and article in BioSpace.